Takeda's translational cell therapy group revs up for a race to the clinic with off-the-shelf CAR-T
Four years after Takeda launched a wide-ranging induced pluripotent stem cell project with the researchers at Nobel prize-winning Shinya Yamanaka’s lab at the University of Kyoto, the pharma company is taking delivery of the first of what it hopes will be a whole pipeline of iPS cell-derived therapies that can deliver on the promise of off-the-shelf CAR-T therapies.
From here, Stefan Wildt — the head of pharma sciences and translational cell therapy at Takeda — and his group of 100-plus scientists will be charged with steering their way to the clinic as they build out the manufacturing and support work for this pipeline-in-the-making.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,600+ biopharma pros reading Endpoints daily — and it's free.